Immunovia AB (publ) (IMMVF) Stock Price, News & Analysis

Company Overview

Immunovia AB (publ) is a Swedish molecular diagnostics company focused on developing blood-based tests for the early detection of cancer. The company’s technology was designed to analyze patterns in the immune system that may indicate the presence of disease, with the goal of supporting earlier diagnosis through minimally invasive testing.

Its principal product candidate was IMMray PanCan-d, a blood test developed to detect pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. The test was intended primarily for people considered to be at elevated risk, including individuals with a significant family history or inherited predisposition to pancreatic cancer. Immunovia developed the product using its proprietary IMMray platform and conducted clinical studies in the United States and Europe.

Founded in Lund, Sweden, Immunovia built its operations around collaborations with academic institutions, healthcare providers, and research organizations involved in cancer diagnostics. The company later reported that clinical results for IMMray PanCan-d did not meet its performance expectations and announced that it was discontinuing development and commercialization activities related to the test. As a result, information about its ongoing products, operations, and leadership may be limited compared with earlier periods.

Key Stats

• Today's Range: $0.01 to $0.01
• 50-Day Range: $0.01 to $0.02
• 52-Week Range: $0.01 to $0.02
• Volume: N/A
• Average Volume: 12,942 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/29/2013
• Today: 10/29/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:IMMVF
• CIK: N/A
• Web: www.immunovia.com
• Phone: (902) 492-1819
• Fax: N/A
• Employees: 69
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A